NovoCure (NVCR) Net Cash Flow Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 83.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.91% |
| Dec 31, 2025 | -949.62% |
| Sep 30, 2025 | 831.48% |
| Jun 30, 2025 | 107.77% |
| Mar 31, 2025 | -117.17% |
| Dec 31, 2024 | -126.76% |
| Sep 30, 2024 | 2,435.48% |
| Jun 30, 2024 | -891.50% |
| Mar 31, 2024 | 203.62% |
| Dec 31, 2023 | 166.89% |
| Sep 30, 2023 | 99.28% |
| Jun 30, 2023 | -116.53% |
| Mar 31, 2023 | 494.10% |
| Dec 31, 2022 | 73.32% |
| Sep 30, 2022 | -137.44% |
| Jun 30, 2022 | 409.22% |
| Mar 31, 2022 | -122.47% |
| Dec 31, 2021 | -4,596.91% |
| Sep 30, 2021 | 775.84% |
| Jun 30, 2021 | 134.33% |
| Mar 31, 2021 | 2,286.68% |
| Dec 31, 2020 | 134.28% |
| Sep 30, 2020 | 33.66% |
| Jun 30, 2020 | -47.20% |
| Mar 31, 2020 | -71.30% |
| Dec 31, 2019 | -277.42% |
| Sep 30, 2019 | 230.42% |
| Jun 30, 2019 | 880.55% |
| Mar 31, 2019 | -64.68% |
| Dec 31, 2018 | 600.43% |
| Sep 30, 2018 | 240.31% |
| Jun 30, 2018 | 164.91% |
| Mar 31, 2018 | 337.03% |
| Dec 31, 2017 | 77.76% |
| Sep 30, 2017 | -92.82% |
| Jun 30, 2017 | 87.48% |
| Mar 31, 2017 | -299.20% |
| Dec 31, 2016 | -273.72% |
| Sep 30, 2016 | 815.70% |
| Jun 30, 2016 | -208.76% |
| Mar 31, 2016 | -121.02% |
| Dec 31, 2015 | 140.69% |